Novelion Therapeutics Inc (NVLN)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

C/O NORTON ROSE FULBRIGHT VANCOUVER, BRITISH COLUMBIA, CANADA V6B 0M3

Qlt Inc. operates as a bio-pharmaceutical company that discovers, develops and commercializes therapies to treat eye diseases, cancer and dermatological conditions. Focuses on photodynamic therapy, a field of medicine that uses photosensitizers (light-activated drugs) in the treatment of disease.

Data as of 2019-12-02 15:00:35 -0500
Market Cap13.341 Million Shares Outstanding19.619 Million Avg 30-day Volume
P/E Ratio Dividend Yield EPS-5.69
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE Enterprise Value
Total Cash Current Debt Gross Profit
BETA 52-week High/Low2.35 / 0.5504 Next Earnings Date Price to Cash FLow (P/CF)
Data provided by IEX Cloud
View SEC Filings from NVLN instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 1 1 0.0% (0.0%) (0.0%)
13F shares: 1 1 0.0%
% Ownership
New Positions:
Increased Positions
Closed Positions
Reduced Positions
Total Calls
Total Puts
PUT/CALL Ratio
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding NVLN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding NVLN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BROADFIN HEALTHCARE MASTER FUND LTD

BROADFIN CAPITAL, LLC

KOTLER KEVIN

  • 10% Owner
2,541,222 2020-01-09 0

STONEPINE CAPITAL, L.P.

  • 10% Owner
3,909,207 2019-12-10 0

CHAN BARBARA Y SEE REMARKS

  • Officer
No longer subject to file 2019-09-24 0

PRICE MICHAEL DENNIS CHIEF FINANCIAL OFFICER

  • Officer
14,111 2019-09-24 0

BUONO LINDA SR. VP, HUMAN RESOURCES

  • Officer
570 2019-05-09 0

LOUIS ROGER SEE REMARKS

  • Officer
1,162 2019-05-09 0

HARSHBARGER BENJAMIN SEE REMARKS

  • Officer
3,683 2019-05-09 0

HACKMAN JEFFREY C.O.O. AND INTERIM C.E.O.

  • Officer
110,351 2018-11-01 0

SABBA STEPHEN L

  • Director
0 2018-08-09 0

THOMAS JOHN C

  • Director
0 2018-08-09 0

ORLOFF JOHN J

  • Director
0 2018-08-09 0

STERN DONALD K

  • Director
0 2018-08-09 0

CORRIGAN MARK

  • Director
0 2018-08-09 0

DIPAOLO MARK

  • Director
0 2018-08-09 0

BRUHN SUZANNE LOUISE

  • Director
0 2018-08-09 0

STEWART MURRAY EXECUTIVE VICE PRESIDENT, R&D

  • Officer
0 2018-02-12 0

ARYEH JASON

  • Director
392,733 2017-05-15 0

PERRY GREGORY D SEE REMARKS

  • Officer
1,683 2017-05-09 0

SZELA MARY T CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
4,384 2017-05-09 0

SMITH SANDFORD D

  • Director
1,048 2017-01-27 0

COX GEOFFREY F

  • Director
0 2016-12-22 0

MENES REMI A SEE REMARKS

  • Officer
0 2016-12-22 0

VANLENT ANNE

  • Director
0 2016-12-22 0

PLUTZKY JORGE MD

  • Director
0 2016-12-22 0

KOTLER KEVIN

  • Director
  • 10% Owner
0 2016-12-22 0

MECKLER JEFFREY A

  • Director
0 2016-06-17 0

KOZARICH JOHN W

  • Director
0 2016-06-17 0

IBBOTT WILLIAM GLEN SVP, FINANCE & CFO

  • Officer
0 2016-06-17 0

ASSALY DORI CHRISTINE SVP, LEGAL & CORP. SECY.

  • Officer
0 2016-06-17 0

JANES LANA ELIZABETH SR. VICE PRES. - SEE REMARKS

  • Officer
0 2016-06-17 0

AEGERION PHARMACEUTICALS, INC.

  • 10% Owner
0 2016-06-14 0

AXIAL CAPITAL MANAGEMENT, LLC

ANDERSEN MARC

ASSOULINE, ELIAV

  • 10% Owner
0 2015-06-16 0

AXIAL CAPITAL MASTER, L.P.

  • 10% Owner
0 2015-06-16 0

NB PUBLIC EQUITY K/S

SCHONHARTING FLORIAN

  • 10% Owner
6,447,626 2014-07-11 0

AUXILIUM PHARMACEUTICALS INC

  • 10% Owner
0 2014-06-25 0

LUSSOW ALEXANDER R SR. VP, BUS. DEV. & COMM. OP.

  • Officer
0 2013-11-22 0

ANIDO VICENTE JR

  • Director
0 2013-07-15 0

JAGPAL SUKHI CHIEF FINANCIAL OFFICER

  • Officer
0 2013-07-15 0

LUPINI LINDA SENIOR VP, HR & ORG. DEV.

  • Officer
15,000 2012-08-13 0

CORMATRIX CARDIOVASCULAR INC

  • Director
0 2012-07-10 0

CLARKE C BOYD

  • FORMER DIRECTOR
No longer subject to file 2012-07-09 0

MULLER CHRISTOPHER A. SEE REMARKS

  • Officer
0 2012-04-16 0

BUTCHOFSKY ROBERT PRESIDENT AND CEO

  • Officer
  • Director
168,847 2012-03-20 0

CADDEN SUZANNE SVP, DEVELOPMENT

  • Officer
0 2011-09-14 0

NB PUBLIC EQUITY K/S

SCHONHARTING FLORIAN

MADSEN CORA

  • 10% Owner
7,397,626 2011-08-30 0

NB PUBLIC EQUITY K/S

HANSEN CHRISTIAN

SCHONHARTING FLORIAN

  • 10% Owner
7,527,613 2011-08-29 0

CARTER BRUCE L A

  • Director
0 2011-05-26 0

CROSSGROVE PETER A

  • Director
0 2011-05-26 0

WOOD JACK

  • Director
0 2011-05-26 0

MASSEY IAN J

  • Director
0 2011-05-26 0

FALBERG KATHRYN E

  • Director
0 2011-05-26 0

TURNER JOSEPH L

  • Director
0 2011-05-26 0

NELSON CAMERON SENIOR VP, FINANCE AND CFO

  • Officer
0 2011-05-25 0

PANIGRAHI DIPAK SVP, R&D AND CMO

  • Officer
0 2010-05-21 0

AXIAL CAPITAL MANAGEMENT, LLC

  • 10% Owner
5,476,229 2010-01-29 0

HAO YONG VICE PRESIDENT, DEVELOPMENT

  • Officer
6,591 2009-03-11 0

NB PUBLIC EQUITY K/S

NB PUBLIC EQUITY KOMPLEMENTAR APS

MADSEN CORA

HANSEN CHRISTIAN

SCHONHARTING FLORIAN

  • 10% Owner
6,513,579 2009-01-30 0

SIMONS JAMES H

RENAISSANCE TECHNOLOGIES LLC

  • PLEASE SEE FOOTNOTE (1)PLEASE SEE FOOTNOTE (1)
5,687,587 2009-01-30 0

HAYES THERESE VP, INVESTOR RELATIONS

  • Officer
No longer subject to file 2008-07-31 0

MENDELSON ALAN C

  • Director
No longer subject to file 2008-05-14 0

WATTIER DANIEL J VP, MARKETING & SALES

  • Officer
No longer subject to file 2008-03-31 0

SCOTT E DUFF

  • Director
No longer subject to file 2007-12-31 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments